Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Nicolas Chouin

Showing results (1-10 of 31) with videos related to

Pageof 4
Sort By:
Current Radiopharmaceuticals|December 29, 2011
Alpha-particle microdosimetryNicolas Chouin, Manuel Bardies
Cancer Biotherapy & Radiopharmaceuticals|April 28, 2007
Implementing dosimetry in GATE: dose-point kernel validation with GEANT4 4.8.1Ludovic Ferrer, Nicolas Chouin, Abdalkader Bitar, et al.
Cancer Biotherapy & Radiopharmaceuticals|August 22, 2009
Comparison of electron dose-point kernels in water generated by the Monte Carlo codes, PENELOPE, GEANT4, MCNPX, and ETRANHelena Uusijärvi, Nicolas Chouin, Peter Bernhardt, et al.
Cancer Biotherapy & Radiopharmaceuticals|July 27, 2007
Implementation of a microdosimetric model for radioimmunotherapeutic alpha emittersNicolas Chouin, Abdalkader Bitar, Albert Lisbona, et al.
Cancer Biotherapy & Radiopharmaceuticals|September 29, 2018
Promising Scandium Radionuclides for Nuclear Medicine: A Review on the Production and Chemistry up to In Vivo Proofs of ConceptSandrine Huclier-Markai, Cyrille Alliot, Rabha Kerdjoudj, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|October 1, 2016
Cure of Human Ovarian Carcinoma Solid Xenografts by Fractionated α-Radioimmunotherapy with <sup>211</sup>At-MX35-F(ab')<sub>2</sub>: Influence of Absorbed Tumor Dose and Effect on Long-Term SurvivalTom Bäck, Nicolas Chouin, Sture Lindegren, et al.
European Journal of Nuclear Medicine and Molecular Imaging|February 18, 2017
The "reset button" revisited: why high activity <sup>131</sup>I therapy of advanced differentiated thyroid cancer after dosimetry is advantageous for patientsFrederik A Verburg, Markus Luster, Luca Giovanella, et al.
Nature Reviews. Clinical Oncology|November 9, 2011
Clinical radioimmunotherapy--the role of radiobiologyJean-Pierre Pouget, Isabelle Navarro-Teulon, Manuel Bardiès, et al.
Cancer Biotherapy & Radiopharmaceuticals|November 18, 2011
In vivo distribution of avidin-conjugated MX35 and (211)At-labeled, biotinylated poly-L-lysine for pretargeted intraperitoneal α-radioimmunotherapySofia Helena Linnea Frost, Tom Bäck, Nicolas Chouin, et al.
Nuclear Medicine and Biology|March 12, 2014
DNA damage-centered signaling pathways are effectively activated during low dose-rate Auger radioimmunotherapyBérengère Piron, Salomé Paillas, Vincent Boudousq, et al.
Pageof 4

Showing results (1-10 of 31) with videos related to

Sort By:
Pageof 4
Current Radiopharmaceuticals|December 29, 2011
Alpha-particle microdosimetryNicolas Chouin, Manuel Bardies
Cancer Biotherapy & Radiopharmaceuticals|April 28, 2007
Implementing dosimetry in GATE: dose-point kernel validation with GEANT4 4.8.1Ludovic Ferrer, Nicolas Chouin, Abdalkader Bitar, et al.
Cancer Biotherapy & Radiopharmaceuticals|August 22, 2009
Comparison of electron dose-point kernels in water generated by the Monte Carlo codes, PENELOPE, GEANT4, MCNPX, and ETRANHelena Uusijärvi, Nicolas Chouin, Peter Bernhardt, et al.
Cancer Biotherapy & Radiopharmaceuticals|July 27, 2007
Implementation of a microdosimetric model for radioimmunotherapeutic alpha emittersNicolas Chouin, Abdalkader Bitar, Albert Lisbona, et al.
Cancer Biotherapy & Radiopharmaceuticals|September 29, 2018
Promising Scandium Radionuclides for Nuclear Medicine: A Review on the Production and Chemistry up to In Vivo Proofs of ConceptSandrine Huclier-Markai, Cyrille Alliot, Rabha Kerdjoudj, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|October 1, 2016
Cure of Human Ovarian Carcinoma Solid Xenografts by Fractionated α-Radioimmunotherapy with <sup>211</sup>At-MX35-F(ab')<sub>2</sub>: Influence of Absorbed Tumor Dose and Effect on Long-Term SurvivalTom Bäck, Nicolas Chouin, Sture Lindegren, et al.
European Journal of Nuclear Medicine and Molecular Imaging|February 18, 2017
The "reset button" revisited: why high activity <sup>131</sup>I therapy of advanced differentiated thyroid cancer after dosimetry is advantageous for patientsFrederik A Verburg, Markus Luster, Luca Giovanella, et al.
Nature Reviews. Clinical Oncology|November 9, 2011
Clinical radioimmunotherapy--the role of radiobiologyJean-Pierre Pouget, Isabelle Navarro-Teulon, Manuel Bardiès, et al.
Cancer Biotherapy & Radiopharmaceuticals|November 18, 2011
In vivo distribution of avidin-conjugated MX35 and (211)At-labeled, biotinylated poly-L-lysine for pretargeted intraperitoneal α-radioimmunotherapySofia Helena Linnea Frost, Tom Bäck, Nicolas Chouin, et al.
Nuclear Medicine and Biology|March 12, 2014
DNA damage-centered signaling pathways are effectively activated during low dose-rate Auger radioimmunotherapyBérengère Piron, Salomé Paillas, Vincent Boudousq, et al.
Pageof 4